CAMBRIDGE, England–(BUSINESS WIRE)–AstraZeneca: Revenue and EPS summary 9M 2026 % Change Q3 2026 % Change $m Actual CER1 $m Actual CER – Product Sales 43,962 7 5 15,066 5 5 – Alliance Revenue 2,806 33 32 1,107 36 36 Product Revenue 46,768 8 6 16,173 7 7 Collaboration Revenue 113 22 23 36 >3x >3x Total Revenue 46,881 8 7 16,209 7 7 Reported EPS ($) 5.62 10 11 2.02 23 26 Core2 EPS ($) 8.00 14 14 2.79 17 19 Key performance elements for 9M 2026 (Growth numbers at constant exchange rates
